Vima Therapeutics doses first participant in Phase 2 trial of daily pill VIM0423 for persistent tremor

Roughly a third of people taking standard levodopa or dopamine agonists find that one stubborn symptom refuses to quieten down. While stiffness and slowness often respond well to routine medication, tremor can play by its own rules, continuing to disrupt everything from holding a morning cuppa to typing a quick message. On 5 November 2026, Boston biotech company Vima Therapeutics took a practical step toward tackling this exact frustration by dosing the first participant in its Phase 2 Vista PD clinical trial. Backed by fresh grant funding from The Michael J. Fox Foundation, the trial is testing an experimental once daily oral medication called VIM0423. Rather than simply adding more dopamine to the system, this treatment looks at the other side of the brain's chemical seesaw. Smooth movement relies on a delicate tug of war between two chemical messengers: dopamine and acetylcholine. When dopamine levels drop, acetylcholine effectively takes over the room, firing off excessive signals that trigger involuntary shaking and muscle contractions. Neurologists have actually known for decades that blocking acetylcholine receptors, specifically those known as muscarinic receptors, can calm tremor down. The catch has always been the side effects. Older drugs that block these receptors act like a blunt instrument throughout the body and brain, causing dry mouth, blurred vision, memory fog, and fatigue, making them unpleasant or unsuitable for long term daily use. To get around this historical roadblock, Vima Therapeutics licensed specialised research from the Children's Mercy hospital system in Kansas City to engineer a smarter, two part combination pill. According to clinical trial registries, VIM0423 pairs two active ingredients, currently known by their lab codes VMA 1001 and VMA 1002, into a single daily regime. The clever idea behind this dual approach is to quieten the overactive muscarinic receptors in the brain that drive the shaking, while shielding the rest of the body from the irritating side effects that held older treatments back. Earlier Phase 1 testing over 28 days showed the medication was safe and well tolerated even at higher target doses, paving the way for this larger study. Digging into the details of the Vista PD study reveals how researchers are putting the medication to the test in real life. The trial is recruiting 80 adults aged 18 to 65 across 30 clinical sites in the United States and Canada. Everyone taking part is already on stable oral dopamine therapy yet still deals with bothersome shaking, and has not had deep brain stimulation or focused ultrasound surgery. Participants are split evenly to receive either the real medication or a matching placebo once a day for seven weeks. Instead of relying solely on brief clinic visits where symptoms might not even show up on cue, participants are wearing continuous movement tracking sensors at home alongside keeping their own daily symptom diaries. This gives scientists an honest, round the clock picture of whether the pill genuinely steadies hands during everyday tasks and improves quality of life over a six to seven week window. Alongside this tremor study, the exact same tablet is currently being tested in a separate Phase 2 trial called Stride Dystonia for isolated dystonia, a condition marked by painful muscle spasms that shares the same chemical imbalance between dopamine and acetylcholine. Because no oral medication has ever been approved specifically to target stubborn tremor in the condition, the results of the Vista PD trial will be closely watched when initial findings are released in the second half of 2027.